Huiling Chen | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Huiling Chen | Oncology | Best Researcher Award 

Physician | Lanzhou University | China

Dr. Huiling Chen is a distinguished physician and researcher at The Second Hospital and Clinical Medical School, Lanzhou University, recognized for her significant contributions to the field of hematologic malignancies, particularly acute myeloid leukemia (AML). Her research primarily focuses on advancing evidence-based therapeutic strategies through systematic reviews and meta-analyses that inform clinical decision-making and improve patient outcomes. As the lead investigator and corresponding author of a comprehensive meta-analysis published in the Annals of Hematology, Dr. Chen evaluated the efficacy and safety of venetoclax plus azacitidine regimens in relapsed or refractory AML, providing vital insights into their clinical utility and identifying combination chemotherapy as a promising approach for improving remission outcomes. Her expertise lies in clinical epidemiology, biostatistics, and the design and interpretation of complex data in oncology research. Through collaborations with multidisciplinary teams across national and international institutions, she has contributed to multicenter studies that bridge gaps between clinical research and real-world applications. Her scholarly work exemplifies a commitment to scientific rigor, innovation, and translational relevance, with her findings influencing the direction of future clinical trials and treatment paradigms for high-risk AML populations. Dr. Chen’s research efforts aim to optimize therapeutic interventions, enhance personalized treatment planning, and advance precision medicine in hematology. Beyond her academic accomplishments, she upholds a strong dedication to mentoring and fostering collaborative research environments that encourage cross-institutional partnerships and scientific dialogue. Her contributions embody the integration of analytical excellence, clinical insight, and humanitarian vision, underscoring her role as a leader shaping the future of hematologic cancer research and its impact on global health.

Profile: ORCID 

Publications

1. Chen, H., Li, X., Gao, L., Zhang, D., & Han, T. (2022, August). Construction and identification of an immortalized rat intestinal smooth muscle cell line. Neurogastroenterology & Motility.

2. Chen, H., Ren, X., Xu, S., Zhang, D., & Han, T. (2022, July). Optimization of lipid nanoformulations for effective mRNA delivery. International Journal of Nanomedicine.

3. Chen, H., Han, T., Gao, L., & Zhang, D. (2022, January). The involvement of glial cell-derived neurotrophic factor in inflammatory bowel disease. Journal of Interferon & Cytokine Research.

4. Chen, H., Zeng, P., & Zhang, D. (2020, February). Haemophagocytic syndrome triggered by acute lymphoblastic leukaemia with t(9;22)(p24; q11.2). Journal of International Medical Research.

Niladry Sekhar Ghosh | Oncology | Best Researcher Award

Published on by Health Scientists

Prof. Niladry Sekhar Ghosh | Oncology | Best Researcher Award

Professor | Assam Down Town University, Guwahati | India

Prof. Niladry Sekhar Ghosh is a distinguished researcher and Professor at Assam Down Town University, Guwahati, serving also as Member Secretary of the Board of Studies, with extensive expertise in pharmaceutical sciences, medicinal chemistry, and biomedical research. He earned his B.Pharm. and M.Pharm. degrees from S.C.S College of Pharmacy, R.G.U.H.S Bangalore, graduating with first-class honors, and completed his Ph.D. at Shobhit University in 2020, focusing on the synthesis of bioactive fluoro-benzothiazole derivatives and the biosynthesis of metallic nanoparticles for biological and pharmacological screening. With over 18 years of teaching experience and significant contributions to research, his key areas of interest include drug discovery, medicinal chemistry, nanotechnology-based drug delivery systems, pharmacological evaluation of bioactive compounds, and cancer therapeutics. Prof. Ghosh has authored more than 50 publications in high-impact journals indexed in SCI, Scopus, and ESCI, including studies on cathepsin inhibitors, benzimidazole and indole derivatives as anticancer agents, and green synthesis of nanoparticles. He has been recognized with multiple honors, notably the Young Teacher Awards by SPER in 2016 and 2018, and has secured competitive research grants from SERB-DST, DBT, ICMR, and NCW for innovative projects in pharmaceutical biotechnology and nanomedicine. Additionally, he holds patents for metallic nanoparticle synthesis and biomedical devices. Beyond research, he serves as a resource person, reviewer, and editor for various scientific journals, contributing to the dissemination of knowledge in medicinal chemistry, pharmacology, and nanotechnology. His leadership roles in academic administration and research guidance underscore his commitment to advancing pharmaceutical education and translational research. He has 90 citations from 22 documents with an h-index of 7.

Profiles: Google Scholar | Scopus | ORCID

Publications

1. Dubey, A., Ghosh, N. S., & Singh, R. (2022). Zebrafish as an emerging model: An important testing platform for biomedical science.

2. Dubey, A., Ghosh, N. S., Gupta, A., & Singh, S. (2023). A review on current epidemiology and molecular studies of lumpy skin disease virus—An emerging worldwide threat to domestic animals.

3. Dubey, A., Ghosh, N. S., Agnihotri, N., Kumar, A., Pandey, M., & Nishad, S. (2022). Herbs derived bioactive compounds and their potential for the treatment of neurological disorders.

4. Dubey, A., Ghosh, N. S., Rathor, V. P. S., Patel, S., Patel, B., & Purohit, D. (2022). SARS-CoV-2 infection leads to neurodegenerative or neuropsychiatric diseases.

5. Chandra, D., Yadav, I. K., Jaiswal, D., Ghosh, N., Singh, H. P., Mishra, A., … (Year not specified). Formulation and evaluation of satranidazole microspheres for colon-targeted drug delivery.

Dana Chase | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Dana Chase | Oncology | Best Researcher Award

Professor at University of California| United States

Dr. Dana M. Chase is a distinguished gynecologic oncologist whose career integrates clinical excellence, academic leadership, and impactful research. As an associate professor and fellowship program director, she has significantly advanced women’s cancer care through innovative research, particularly in ovarian, cervical, and uterine malignancies, with her findings widely published in leading journals and presented at major international conferences. Her academic training and subspecialty expertise provide a strong foundation for her role in bridging clinical practice with evidence-based research, while her leadership in mentoring fellows and trainees highlights her dedication to education. Dr. Chase has also been recognized with numerous awards for patient care, teaching, and research, underscoring her influence across multiple domains. Beyond academia, she contributes actively to community engagement and patient advocacy, further broadening the reach of her work. With a clear commitment to advancing gynecologic oncology and inspiring future researchers, she stands out as an exemplary candidate for recognition.

Professional Profile

Scopus Profile | ORCID Profile

 

Education

Dr. Dana M. Chase has pursued a comprehensive and rigorous educational path that laid the foundation for her distinguished career in gynecologic oncology. She began her academic journey with an undergraduate degree in Latin American Studies, followed by postbaccalaureate premedical studies that strengthened her scientific background. She then earned her medical degree, which was followed by a residency in obstetrics and gynecology, where she gained extensive clinical training and developed a strong interest in women’s health and oncology. Building upon this, she completed a highly specialized fellowship in gynecologic oncology, where she refined her expertise in managing complex gynecologic cancers and gained advanced skills in both research and clinical practice. This blend of humanities, medical training, and subspecialty fellowship has enabled her to combine a compassionate, patient-centered approach with scientific rigor. Her educational background not only shaped her clinical and research capabilities but also prepared her for leadership in academic medicine.

Experience

Dr. Dana M. Chase has built an impressive professional career that spans academic medicine, clinical practice, and research leadership in gynecologic oncology. She has served in key academic roles, including assistant, associate, and full professorships at leading medical institutions, where she has combined teaching, mentorship, and program development with advancing cancer care. As a fellowship program director, she has guided the training of future specialists, emphasizing innovation, evidence-based practice, and patient-centered care. Clinically, she has held positions as a gynecologic oncologist across major hospitals and cancer centers, where she provided advanced surgical and medical management for women with complex cancers. Her leadership extends beyond the clinic into research, with active participation in national and international collaborations, presentations at major conferences, and contributions to peer-reviewed publications. Recognized for her excellence in teaching, patient care, and research, Dr. Chase’s professional journey highlights her as a dedicated physician, educator, and influential researcher.

Research Interest

Dr. Dana M. Chase’s research interests center on advancing the understanding and treatment of gynecologic cancers, with a strong focus on ovarian, cervical, and uterine malignancies. She is particularly committed to exploring novel therapeutic approaches, including the integration of targeted therapies and innovative clinical trial designs that aim to improve patient survival and quality of life. Her work also extends to studying the role of the vaginal microbiome, inflammation, and genetic factors in cancer development and progression, highlighting her interest in precision medicine and translational research. Dr. Chase has been actively involved in collaborative projects that bridge laboratory science with clinical applications, ensuring that discoveries translate into tangible benefits for patients. Additionally, she is passionate about survivorship research, patient advocacy, and educational outreach, which complement her scientific contributions by addressing the holistic needs of women with cancer. Her research embodies a vision of innovation, collaboration, and improved patient outcomes.

Award and Honor

Dr. Dana M. Chase has received numerous awards and honors that reflect her excellence in research, teaching, clinical care, and leadership in gynecologic oncology. Early in her career, she was recognized with prestigious research and presentation awards from leading professional organizations, acknowledging her contributions to advancing the understanding and management of gynecologic cancers. She has earned accolades such as merit and travel awards from oncology foundations, humanitarian and teacher of the year honors, and recognition for outstanding research papers and clinical presentations. Her commitment to patient care has also been highlighted through physician recognition awards and consistent listings among top doctors in major medical publications. These distinctions not only demonstrate her academic and clinical achievements but also underscore her influence as a mentor, educator, and advocate. Collectively, her awards and honors signify a career dedicated to innovation, excellence, and service, establishing her as a respected leader in women’s health and oncology.

Research Skill

Dr. Dana M. Chase possesses a wide range of research skills that reflect her expertise in gynecologic oncology and her commitment to advancing scientific knowledge in women’s cancer care. She is highly skilled in designing and conducting clinical trials, particularly those exploring new therapeutic strategies, targeted treatments, and survivorship outcomes. Her ability to integrate translational research with clinical applications demonstrates proficiency in bridging laboratory findings with patient-centered interventions. She has extensive experience in data analysis, interpretation of complex clinical outcomes, and dissemination of results through peer-reviewed publications and international conference presentations. Additionally, she is adept at developing collaborative research initiatives, both nationally and internationally, fostering multidisciplinary partnerships that enhance the scope and impact of her work. Her research skills extend beyond technical expertise to include mentorship, as she effectively guides trainees and junior researchers in developing their scholarly work. Collectively, these strengths underscore her role as a capable and innovative researcher.

Publications Top Notes

Title: Navigating complexities of polymorphic microbiomes in endometrial cancer
Authors: Dana M. Chase, et al.

Title: Real-world post-2020 first-line maintenance treatment patterns in patients with advanced ovarian cancer in the US
Authors: Dana M. Chase, et al.

Title: Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel
Authors: Dana M. Chase, et al.

Title: Treatment patterns and outcomes by mismatch repair/microsatellite instability status among patients with primary advanced or recurrent endometrial cancer in the United States
Authors: Dana M. Chase, et al.

Title: Clinical Trial Screening in Gynecologic Oncology: Defining the Need and Identifying Best Practices
Authors: Dana M. Chase, et al.

Conclusion

In conclusion, Dr. Chase is a highly deserving candidate for the Best Researcher Award, as her contributions demonstrate excellence in clinical care, education, and translational research. Her leadership in advancing gynecologic oncology, dedication to training the next generation of specialists, and consistent engagement in impactful research reflect a career committed to improving both science and society. With her proven track record of innovation and service, combined with the potential to expand into new frontiers of cancer research, she stands as a strong role model and an exemplary figure in the academic and medical community.